泡泡瑪特(09992.HK)：上半年營收人民幣171.73億元，同比增長23.8%；本公司擁有人應占溢利50.38億元，同比10.1%。

摩根大通覆盤前一日科技股回撤時認爲，市場試圖把下跌歸因於長端收益率上升和AI融資壓力，但交易臺看到的更像一次低成交、缺乏催化劑、財報季後的動量反轉。股票交易員形容當日資金流活躍度只有“3/10”，半導體確有局部降風險，但規模並不大。且團隊的綜合倉位指標仍只有約40%分位，處於中性水平。費城半導體ETF即便經歷回落，仍比7月低點高約18%。因此繼續維持技術性牛市判斷，並認爲後續企業回購、散戶及系統化資金都有重新加倉或提高槓杆的空間。

Xiansheng Pharmaceutical on Aug. 20 said it has struck a strategic cooperation with Ruiyang (Shandong) Biopharmaceutical on the domestic Class-1 biologic new drug Kulaivebai mAb injection. Under the deal Xiansheng will hold exclusive commercialization rights in Greater China. The marketing authorisation application has been accepted by the National Medical Products Administration’s Center for Drug Evaluation (CDE) and placed in priority review. The company said the collaboration will strengthen its anti-infectives product portfolio.